POET Technologies has secured a $50 million purchase order from Lumilens, with potential to exceed $500 million if production scales successfully. Despite previous governance issues and losing a partnership with Marvell, the company’s long-term opportunity in AI optical connectivity remains strong. A recent $400 million capital raise has improved its financial position, shifting investor focus from financing risks to execution risks. The stock trades at high multiples, reflecting expectations of future commercial success rather than current revenue levels.
AXT, Inc. has secured a long-term supply deal with Lumentum Holdings, reinforcing its role in providing indium phosphide wafers for advanced tech products. The company projects a nearly 90% revenue increase, fueled by strong demand from the AI sector...
Sanofi has published its half-year financial report for the period ending June 30, 2026, available on its website and filed with regulatory authorities in France and the US. The report highlights Sanofi's strong business performance, including double...
Sanofi has published its financial report for the first half of 2026, available on its website and filed with the French financial authority (AMF). The biopharmaceutical company highlights its innovation in R&D and use of AI to drive long-term growth...
Robert W. Baird raised Humana's stock price target to $390 from $205, signaling potential upside despite a 5.87% stock drop on a turbulent market day. Meanwhile, Raymond James downgraded Humana to Market Perform, indicating expected performance in li...
Evercore ISI has increased its price target for Teradyne to $420 from $370, maintaining an Outperform rating due to the company's robust AI-driven growth. Teradyne reported record Q2 revenues of $1.33 billion, a 103.9% increase year-over-year, and no...
